Finance & Capital Markets

  1. Serial Success With Triumvira's Rob Williamson 3/10/2024

    Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Learn secrets to his serial success on this week's Business of Biotech podcast.

  2. Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier 11/5/2025

    On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. 

  3. Biotech Story Time With Tal Zaks, M.D. (Part 2) 1/5/2025

    Dr. Tal Zaks joins the Business of Biotech for the second part of "Story Time With Tal," discussing his transition from Moderna's CMO during the COVID-19 pandemic to co-founding Exsilio Therapeutics, an mRNA startup. The episode explores Exsilio's foundation, scientific focus, team recruitment, and its $82 million Series A funding led by Novartis Venture Fund and Delos Capital, with support from prominent investors like OrbiMed, CRISPR Therapeutics, and J.P. Morgan Life Sciences Private Capital.

  4. Biotech Cash Management With Allan Shaw 8/2/2023

    It’s been said that clinical trials are where emerging biotechs go to die. If the science doesn't kill quickly, poor cash management will slowly. On this week's episode of the Business of Biotech, our favored biotech finance management maven, Allan Shaw, offers pointed advice on stretching cash runways for the long run.

  5. BoB@JPM: Ron Cooper, enGene 1/21/2026

    On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders.

  6. Embracing Biotech Chaos With Memo's Erik van den Berg 9/8/2024

    Erik van den Berg is CEO and board member at Memo Therapeutics, and he's a student of biotech chaos. In fact, he's been embracing it with intention for the past 30 years. On this episode of the Business of Biotech, he walks us through the management of that chaos in specific detail.

  7. Serving The Underserved With Gates MRI's Claire Wagner, M.D. 11/10/2024

    On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's Dr. Claire Wagner joins us to share insights into her work as head of Corporate Strategy and Market Access there.

  8. The Innovation Reduction Act With Allan Shaw 5/31/2023

    Allan Shaw posits that the Inflation Reduction Act (IRA) will stifle momentum in the biopharma industry and suggests its impact will ultimately cost patients and payers more. Tune in to learn why.

  9. Biotech Collaboration Strategy With IGI's Cyril Konto, M.D. 11/20/2025

    On this week's Business Of Biotech episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration.

  10. Deal And Investment Trends With Investment Banker David Sans 4/2/2025

    Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional background that began in Big Pharma and shifted to investing over 15 years ago.